Relation between intestinal MICRObiota translocation and development of Graves Orbitopathy: the MICRO-GO study

Relation between intestinal MICRObiota translocation and development of Graves Orbitopathy: the MICRO-GO study - MICRO-GO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41329

Enrollment

Registered

2013-06-07

Start date

2013-09-25

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eyedisease associated with hyperthyreoidism Graves orbitopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Caucasian subjects with Graves orbitopathy (males/postmenopauzal females, aged 18 to 69 years-old; and not on concomitant medication besides block/replacement therapy (thyrax en strumazol/PTU))

Exclusion criteria

Exclusion criteria: Use of prednisone/antibiotic in the last three months including proton pump inhibitors (PPI) is prohibited.

Design outcomes

Primary

Measure	Time frame
To determine differences in orbital tissue bacterial content and inflammatory genes expression is associated with clinical disease severity score (CAS) in Graves orbitopathy patients	—

Secondary

Measure	Time frame
Differences in gutmicrobiota composition, mucosal integrity, subsequent endotoxemia and plasma levels of inflammation between subjects with low and high CAS scores in patients with Graves orbitopathy	—

Countries

Netherlands

Outcome results